Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver G Ottmann

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Blood|April 5, 2007
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Heike Pfeifer, Barbara Wassmann, Anna Pavlova, et al.
European Journal of Clinical Pharmacology|October 12, 2012
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemiaFrancis J Giles, Ophelia Q P Yin, William M Sallas, et al.
Cancer|October 19, 2019
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemiaAlessandro Rambaldi, Josep-Maria Ribera, Hagop M Kantarjian, et al.
The New England Journal of Medicine|September 3, 2015
Telomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaGabriela M Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G Ottmann, et al.
BMC Pharmacology & Toxicology|September 30, 2020
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemiaFabian Lang, Lydia Wunderle, Susanne Badura, et al.
Cancer|November 19, 2005
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaGesine Bug, Markus Ritter, Barbara Wassmann, et al.
Cancer|March 7, 2007
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisisStefan Fruehauf, Julian Topaly, Eike C Buss, et al.
British Journal of Haematology|August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaMichael Dickinson, David Ritchie, Daniel J DeAngelo, et al.
British Journal of Haematology|June 9, 2018
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemiaOliver G Ottmann, Carsten Müller-Tidow, Alwin Krämer, et al.
International Journal of Cancer|June 3, 2016
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survivalSarah Oelsner, Juliane Wagner, Miriam E Friede, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Blood|April 5, 2007
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Heike Pfeifer, Barbara Wassmann, Anna Pavlova, et al.
European Journal of Clinical Pharmacology|October 12, 2012
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemiaFrancis J Giles, Ophelia Q P Yin, William M Sallas, et al.
Cancer|October 19, 2019
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemiaAlessandro Rambaldi, Josep-Maria Ribera, Hagop M Kantarjian, et al.
The New England Journal of Medicine|September 3, 2015
Telomerase Inhibitor Imetelstat in Patients with Essential ThrombocythemiaGabriela M Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G Ottmann, et al.
BMC Pharmacology & Toxicology|September 30, 2020
A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemiaFabian Lang, Lydia Wunderle, Susanne Badura, et al.
Cancer|November 19, 2005
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaGesine Bug, Markus Ritter, Barbara Wassmann, et al.
Cancer|March 7, 2007
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisisStefan Fruehauf, Julian Topaly, Eike C Buss, et al.
British Journal of Haematology|August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaMichael Dickinson, David Ritchie, Daniel J DeAngelo, et al.
British Journal of Haematology|June 9, 2018
Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemiaOliver G Ottmann, Carsten Müller-Tidow, Alwin Krämer, et al.
International Journal of Cancer|June 3, 2016
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survivalSarah Oelsner, Juliane Wagner, Miriam E Friede, et al.
Pageof 11